Boston Scientific (NYSE:BSX) Posts Earnings Results, Beats Estimates By $0.02 EPS

Boston Scientific (NYSE:BSX) issued its quarterly earnings results on Wednesday. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02, FiscalAI reports. The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.70 earnings per share.

Here are the key takeaways from Boston Scientific’s conference call:

• Boston Scientific beat 2025 guidance — Q4 revenue of $5.286B (+15.9% reported), FY revenue of $20.074B (+19.9%), Q4 adjusted EPS $0.80 and FY adjusted EPS $3.06 (+22%), with free cash flow of $3.659B (↑38%).
• 2026 outlook guides to full-year organic growth of 10%–11%, adjusted EPS $3.43–$3.49 (12%–14% growth), and 50–75 bps of operating margin expansion, reaffirming the 2026–2028 long‑range targets.
• EP and Watchman are key growth drivers — EP organic growth was 35% in Q4 (73% FY) driven by PFA adoption (~70% of US AF cases), and Watchman grew 29% in Q4; the upcoming Champion trial data at ACC could materially expand Watchman’s indication if positive.
• Near‑term operational headwinds include a product removal for certain Axios sizes and the discontinuation of Acclarent, which the company expects to create a ~150 bps drag on early‑2026 growth and to depress Endo/Urology performance in H1.
• Strategic M&A and healthy balance sheet — closed Nalu, announced Valencia and Penumbra deals to expand adjacencies, strong free cash flow and a 1.9x gross debt leverage ratio with major rating agencies affirming ratings.

Boston Scientific Trading Down 17.1%

Boston Scientific stock traded down $15.71 during trading hours on Wednesday, hitting $75.91. The stock had a trading volume of 8,794,500 shares, compared to its average volume of 12,382,081. The stock has a market cap of $112.53 billion, a price-to-earnings ratio of 40.89, a P/E/G ratio of 1.63 and a beta of 0.67. The business’s 50 day simple moving average is $94.89 and its 200-day simple moving average is $99.29. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. Boston Scientific has a one year low of $77.86 and a one year high of $109.50.

Analyst Upgrades and Downgrades

BSX has been the topic of several research reports. Canaccord Genuity Group lowered their target price on Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a report on Wednesday, December 17th. Wells Fargo & Company lifted their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. BTIG Research reissued a “buy” rating and set a $132.00 price objective on shares of Boston Scientific in a report on Friday, November 21st. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $123.26.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 191,105 shares of company stock worth $18,067,697 in the last three months. Corporate insiders own 0.50% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

A number of large investors have recently added to or reduced their stakes in BSX. Marshall Wace LLP lifted its position in shares of Boston Scientific by 30.7% during the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock worth $956,680,000 after purchasing an additional 2,301,383 shares in the last quarter. Credit Agricole S A purchased a new stake in Boston Scientific during the 3rd quarter worth approximately $204,812,000. Amundi boosted its stake in Boston Scientific by 17.5% in the third quarter. Amundi now owns 11,981,584 shares of the medical equipment provider’s stock valued at $1,158,619,000 after acquiring an additional 1,781,830 shares during the period. Man Group plc boosted its stake in Boston Scientific by 79.8% during the 3rd quarter. Man Group plc now owns 3,843,937 shares of the medical equipment provider’s stock valued at $375,284,000 after purchasing an additional 1,706,494 shares in the last quarter. Finally, Raymond James Financial Inc. raised its holdings in shares of Boston Scientific by 32.8% during the third quarter. Raymond James Financial Inc. now owns 3,157,207 shares of the medical equipment provider’s stock valued at $308,237,000 after acquiring an additional 779,938 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat and healthy top-line growth — BSX reported $0.80 EPS (vs. $0.78 consensus) and net sales of $5.286 billion, up ~15.9% year-over-year, demonstrating continued demand across its businesses. Boston Scientific announces results for fourth quarter and full year 2025
• Positive Sentiment: Analyst backing remains — several firms maintain buy/overweight views and some have raised targets, which supports longer-term sentiment if guidance proves conservative. Boston Scientific Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts
• Neutral Sentiment: Company materials posted — the official press release and slide deck are available for investors who want to dig into segment performance and management commentary. View Press Release
• Neutral Sentiment: Industry context — analysts note medical-products demand is mixed heading into 2026, which may mute upside even if BSX executes. 4 Medical Product Stocks to Watch From a Challenging Industry (Revised)
• Negative Sentiment: Cautious 2026 guidance — management issued a modest revenue-growth outlook and profit guidance below some Street expectations, which analysts and the market flagged as underwhelming and drove a sharp premarket selloff. Boston Scientific shares slide on cautious 2026 revenue forecast
• Negative Sentiment: Market reaction and commentary — coverage notes the Q4 beat but highlights the disappointing outlook as the primary reason for the share decline. Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply.
• Negative Sentiment: Insider selling — CEO Michael Mahoney disclosed a sale of 160,901 shares, which some investors view negatively even though insiders often sell for diversification or tax reasons. Insider Selling: Boston Scientific (NYSE:BSX) CEO Sells 160,901 Shares of Stock

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.